Dr. Denmeade is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
401 N. Broadway
Baltimore, MD 21231Phone+1 410-955-8964- Is this information wrong?
Summary
- Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Director of the Genitourinary Oncology Program at Johns Hopkins in Baltimore, MD. He is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 28 years. He is experienced in treatment of advanced prostate cancer. He has more than 200 publications and developed the concept of Bipolar Androgen Therapy for metastatic prostate cancer
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
University of ChicagoResidency, Internal Medicine, 1989 - 1992
Columbia University Vagelos College of Physicians and SurgeonsClass of 1989
Certifications & Licensure
VA State Medical License 2024 - 2026
MD State Medical License 1993 - 2024
NC State Medical License 2020 - 2022
PA State Medical License 1992 - 2022- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
Clinical Trials
- A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer Start of enrollment: 2010 Mar 01
- Bipolar Androgen-based Therapy for Prostate Cancer (BAT) Start of enrollment: 2013 Jan 01
- Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer Start of enrollment: 2013 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).Wise, D., Pachynski, R., Denmeade, S., Aggarwal, R., Deng, J., Febles, V., Balar, A., Economides, M., Loomis, C., Selvaraj, S., Haas, M., Kagey, M., Newman, W., Baum, ...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 10
- Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.Denmeade, S.> ;Journal of Clinical Oncology. 2024 Mar 1
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.Lalji, A., Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Pall...> ;Nature Communications. 2024 Jan 2
- Join now to see all
Journal Articles
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerEmmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
Press Mentions
Prostate Cancer Drug Is Found to Be an Effective Antiviral Against Coronavirus and the Common ColdFebruary 3rd, 2021
Health Tips: This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 29th, 2017
Health Tips This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 28th, 2017- Join now to see all
Other Languages
- Spanish
Hospital Affiliations
Johns Hopkins HospitalBaltimore, Maryland
Johns Hopkins Bayview Medical CenterBaltimore, Maryland
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/samuel-denmeade
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
